Abstract:According to NCCN guidelines, concurrent chemoradiation (CCRT) is the standard care for locally advanced cervical cancer (LACC) patients , but the benefit of adjuvant chemotherapy (ACT) after CCRT for LACC patients is still controversial. This study is designed to answer the question by comparing the efficacy and toxicities of concurrent chemoradiation (CCRT) with adjuvant chemotherapy (ACT) (CCRT+ACT) versus concurrent chemoradiation (CCRT) alone in LACC. Patients with stage IB2,IIA2,IIB-IVA (2009 FIGO staging) cervical cancer were recruited from June 2013 to June 2018 at 4 cancer centers in China. The patients were randomly assigned to two arms: CCRT +ACT and CCRT alone. All patients were treated with IMRT (external-beam radiotherapy up to 50.4 Gy) with concurrent cisplatin, followed by intra-cavitary brachytherapy. The chemotherapy consisted of concurrent cisplatin(40 mg/m2 weekly) during IMRT, and 3 cycles of adjuvant CT with TP (docetaxel 75 mg/m2, day 1, and cisplatin 25 mg/m2, day 1-3 or carboplatin AUC 4-5 ,day 1)every 3 weeks. The primary endpoint was progression free survival(PFS), and the secondary endpoints included overall survival (OS), locoregional recurrence rate, distance metastasis rate , and toxicities. Survivals were calculated with Kaplan-Meier method. The differences between survivals were calculated with Log-rank test. Toxic effects were analyzed using the χ2 test. All statistical tests were two-sided. A total of 176 patients were recruited in the study and 161 were eligible for intent-for-treat analysis. 82patients were assigned to the CCRT+ACT arm and 79 in the CCRT alone arm. With a median follow-up of 60.1 months, the 5-year PFS and OS of all the patients were 68.32% and72.05%, respectively. The 5-year PFS was 75.61% in the CCRT+ACR arm, and was 60.76% in the CCRT arm. There was significant difference in PFS between the two arms （P=0.043). The 5-year OS was 76.83% in the CCRT+ACT arm and was, and was 67.09% in the CCRTarm. There was no significant difference in OS between the two arms （P=0.169). There was significant difference between the CCRT+ACT and CCRT arms in distant alone recurrence (p=0.048),but not in locoregional recurrence rate (p=0.752).There were significantly higher acute systemic side effects in the CCRT+ACT arm, especially the incidence of grade 3-4 hematologic and gastrointestinal reactions (P =0.000). Most of locoregional recurrence and distant metastases occurred with staging IIIB-IVA patients in the CCRT alone arm. Adjuvant chemotherapy after concurrent cisplatin chemoradiation for LACC patients improves PFS but not improves OS. It reduces distance metastasis but is correlated with poorer response to locoregional recurrence.There were more significant toxicities during adjuvant chemotherapy but it was well tolerated by patients. Further research and longer follow up is needed, especially for the staging IIIB-IVA LACC patients.

Comparison of two platinum-containing chemotherapy regimens in the treatment of advanced cervical cancer with concurrent chemoradiotherapy

Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage Ⅰb2 to Ⅳ a squamous cell carcinoma of the uterine cervix

Clinical outcomes of patients with cervical carcinoma receiving different radiochemotherapy regimens

A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Chinese Patients with Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy after Concurrent Chemoradiotherapy

A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy

Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients

Comparison Of Concurrent Cisplatin Chemoradiotherapy Plus Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy Alone In Locally Advanced Cervical Cancer

Could Adjuvant Chemotherapy Improve Prognosis For Cervical Cancer Patients With Elevated Pretreatment Serum Squamous-Cell Carcinoma Antigen?

The Study of Concurrent Chemoradiotherapy in Medium-Term and Advanced Cervical Carcinoma the Uterine Cer-Vix

Prognosis of Stage ⅠB-ⅡA Cervical Squamous Cell Carcinoma Patients with Intermediate Risk Factors Treated with Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy: A Prospective Randomized Controlled Trial

Comparisons of Survivals and Toxicities Between Young and Elderly Patients with Cervical Cancer Treated with Definitive Radiotherapy or Concurrent Chemoradiotherapy

Comparison of Different Adjuvant Therapy after Radical Surgery in Early Stage Cervical Carcinoma: A 3-Arm Randomized Control Study.

Clinical Efficacy and Prognostic Factors in Locally Advanced Cervical Cancer Patients Treated with Concurrent Chemoradiotherapy

Treatment Results of Different Radiotherapy for 763 Patients with Advanced Cervical Cancer

Acute Toxicity Analysis aboute Docetaxel Plus Cisplatin Concurrent Chemotherapy and Radiotherapy in the Treat-ment of Cerrical Cancer

Analysis of clinical efficacy of radiotherapy alone and concurrent chemoradiotherapy in cervical cancer patients with intermediate risk factors after surgery

The Effectiveness and Complications of Different Treatment Modalities After Surgery for Early-Stage High Risk Cervical Carcinoma

Concurrent Cisplatin-Based Chemoradiotherapy Versus Exclusive Radiotherapy in High-Risk Cervical Cancer: a Meta-Analysis

The efficient of chemotherapy weekly in the chemoradiotherapy of cervical cancer

Clinical Effects of Concurrent Radiochemotherapy Followed by Radical Surgery and Radical Radiotherapy with Concurrent Chemotherapy: a Comparative Study of 243 Patients with FIGO Stage ⅡB Cervical Cancer

Therapeutic Efficacy of Three-Dimensional Conformal Radiotherapy Combined with Concurrent Weekly Cisplatin-Based Chemotherapy for Locally Advanced Cervical Cancer